AACR 2022 | Opportunities for novel targets or therapies in TNBC

Lisa A. Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, shares her thoughts on likely sources of progress in novel target and therapy identification for triple negative breast cancer (TNBC). Targeted therapy using antibody-drug conjugates have had some success, but there is still a large portion of TNBC patients with adaptive programming that soon mitigates any benefits. Refinement of current targets and the identification of novel strategies to overcome this challenge will likely be the focus of research in this field. Combinatorial therapy with immunomodulatory drugs and has also been very successful with promising candidates coming down the pipeline. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.